Atara Biotherapeuticsの空売り状況は、投資家がAtara Biotherapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Atara Biotherapeutics (NASDAQ:ATRA) 株価情報, 空売り情報

Atara Biotherapeutics

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics Inc

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 13.7% to $0.99 during Thursday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares increased by 13.32% to $0.27. The company's market cap stands at $17.4 million. </li>
<li>Avanos Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNS#NYSE">AVNS</a>) stock rose 12.55% to $13.99. The market value of their outstanding shares is at $643.5 million. </li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $375.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) shares rose 8.49% to $19.28. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares rose 8.2% to $0.86. The company's market cap stands at $4.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares decreased by 32.6% to $1.26 during Thursday's pre-market session. The company's market cap stands at $39.3 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) stock decreased by 23.45% to $0.15. The company's market cap stands at $26.7 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 22.44% to $0.54. The company's market cap stands at $17.7 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 15.26% to $3.11. The market value of their outstanding shares is at $5.1 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) shares decreased by 13.05% to $6.0. The market value of their outstanding shares is at $35.1 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock decreased by 12.68% to $1.24. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATRA

AVNS

CERO

ENSC

FORA

GLYC

NUWE

NVCR

RLMD

SONN

XFOR

12 Health Care Stocks Moving In Thursday's Pre-Market Session

On March 31, 2025, Atara Biotherapeutics, Inc., (the "Company") entered into an Amendment (the "Amendment") to the Amended and Restated Commercialization Agreement dated October 31, 2023 (the "Agreement") with Pierre Fabre Medicament ("Pierre Fabre"). Under the terms of the Amendment, as of March 31, 2025, the Company has completed the transfer of all manufacturing responsibility to Pierre Fabre and Pierre Fabre will be, at its cost, responsible for manufacturing and supplying tabelecleucel for development and commercialization worldwide. Pierre Fabre has also agreed to assume the costs related to remediation of the third-party manufacturing facility to address the U.S. Food and Drug Administration's (the "FDA") requests to support resubmission of the BLA for tab-cel.
In exchange for accelerating the transfer of all manufacturing responsibility and assumption of such remediation costs by Pierre Fabre, among other things, the Company agreed to reduce the amount of certain potential future regulatory and commercial milestone payments under the Agreement. The Amendment did not change any of the royalties the Company is eligible to receive under the Agreement. Pursuant to the Amendment, the Company is now entitled to receive an aggregate of up to $550.0 million in additional potential milestone payments upon achieving certain regulatory and commercial milestones relating to tab-cel, including up to $40.0 million in potential regulatory milestones in connection with the approval by the FDA of a BLA for tab-cel under the terms of the Agreement (as amended by the Amendment).

News

Contracts

Atara Biotherapeutics Transfers Full Manufacturing Responsibility For Tabelecleucel To Pierre Fabre; Now Entitled To Receive Up To $550M In Additional Potential Milestone Payments Upon Achieving Certain Regulatory And Commercial Milestones Relating To Tab-cel, Including Up To $40M In Potential Regulatory Milestones In Connection With The Approval By The FDA Of A BLA For Tab-cel

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Buy and maintains $17 price target.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $17 Price Target

Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(3.58) by 66.76 percent. This is a 91.5 percent increase over losses of $(14.00) per share from the same period last year. The company reported quarterly sales of $32.753 which missed the analyst consensus estimate of $19.148 million by 100.00 percent. This is a 100.00 percent decrease over sales of $4.252 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Atara Biotherapeutics Q4 2024 GAAP EPS $(1.19) Beats $(3.58) Estimate, Sales $32.753 Miss $19.148M Estimate

HC Wainwright &amp; Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) from Neutral to Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) active Investigational <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43093925/atara-biotherapeutics-provides-update-on-clinical-programs-related-to-ebvallo-tabelecleucel-and-at" rel="noreferrer noopener">New Drug (IND) applications</a>.
These INDs include the EBVALLO&nbsp;(tabelecleucel) program for patients two years of age and older with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), as well as ATA3219, a CAR-T therapy for non-Hodgkin&#8217;s lymphoma and systemic lupus erythematosus.
Specifically, identified subjects currently enrolled in the clinical studies who have the potential to derive clinical benefit may continue to receive treatment.
Screening and enrollment of new participants in both programs have been paused.
The clinical hold for EBVALLO is directly linked to inadequately addressed GMP compliance issues identified during the pre-license inspection of the third-party manufacturing facility referenced in the Complete Response Letter (CRL) for EBVALLO that was <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43026975/atara-biotherapeutics-provides-regulatory-and-business-update-on-ebvallotm-tabelecleucel" rel="noreferrer noopener">announced last week</a>.
While the ATA3219 drug product is manufactured at a separate, fully compliant GMP-certified facility, the compliance issues at the same third-party facility referenced in the CRL affect the starting materials used in its production.
These issues, which underlie both the CRL and the clinical hold, are specific to the referenced third-party manufacturing facility and do not affect Atara&#8217;s second third-party manufacturer, FUJIFILM Diosynth Biotechnologies (FDB) facility in Thousand Oaks, California.
The FDB facility remains a critical component of Atara&#8217;s long-term manufacturing strategy for both assets.
Last week, Atara engaged a financial advisor to support the assessment of opportunities to advance and realize value from Atara&#8217;s CAR-T assets.
Atara says it remains eligible to receive a $60 million milestone payment from Pierre Fabre upon FDA approval of the EBVALLO BLA, as well as significant double-digit tiered royalties as a percentage of net sales and milestones related to EBVALLO&#8217;s commercial sales.
The company added that if a strategic resolution is not reached to provide funding for its CAR-T development programs in the first quarter of 2025, Atara plans to suspend all CAR-T activities and significantly reduce company expenses and activities to only those that support the approval of EBVALLO, including through a near-term progressive transfer of all operational activities related to EBVALLO to Pierre Fabre.
Atara has entered into a non-binding term sheet with Redmile Group to provide up to $15 million in funding through an equity line of credit.
Price Action: ATRA stock is down 4.09% at $6.302 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43098271/canoo-files-bankruptcy-stock-falls-nasa-walmart-dod-usps" target="_blank" rel="noreferrer noopener">EV Startup Canoo Files For Bankruptcy After NASA, USPS, Walmart Partnerships Bear Little Fruit</a></li>
</ul>
Photo via Shutterstock.

Biotech

Health Care

Trading Ideas

General

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

U.S. FDA issues clinical hold on EBVALLO&#x2122; (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL)
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;esheet=54183700&amp;newsitemid=20250121045791&amp;lan=en-US&amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;index=1&amp;md5=c7a54b9aad73e62bc9c74498767d641c">Atara Biotherapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Atara's active Investigational New Drug (IND) applications. These INDs include the EBVALLOTM (tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), as well as ATA3219, an allogeneic CD19-targeted CAR-T therapy, for the treatment of non-Hodgkin's lymphoma and systemic lupus erythematosus. Specifically identified subjects currently enrolled in the clinical studies who have the potential to derive clinical benefit may continue to receive treatment in accordance with the ongoing study protocols. Screening and enrollment of new participants in both programs have been paused.
The clinical hold for EBVALLO is directly linked to inadequately addressed GMP compliance issues identified during the pre-license inspection of the third-party manufacturing facility referenced in the Complete Response Letter (CRL) for EBVALLO that was announced on January 16, 2025. While ATA3219 drug product is manufactured at a separate, fully compliant GMP-certified facility, the starting materials used in its production are affected by the compliance issues at the same third-party facility referenced in the CRL. These issues, which underlie both the CRL and the clinical hold, are specific to the referenced third-party manufacturing facility and do not affect Atara's second third-party manufacturer, FUJIFILM Diosynth Biotechnologies (FDB) facility in Thousand Oaks, California. The FDB facility remains a critical component of Atara's long-term manufacturing strategy for both assets.
Atara and FDA have discussed and agreed upon the actions necessary to release the clinical holds. The FDA has confirmed its commitment to working collaboratively and expeditiously with Atara to resolve the clinical holds.

FDA Places Clinical Hold On Atara Biotherapeutics' EBVALLO And ATA3219 Studies; Linked To Manufacturing Compliance Issues; Enrollment Paused; Existing Subjects May Continue Treatment; Co And FDA Discussed And Agreed Upon Actions For Resolution

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Buy and lowers the price target from $21 to $17.

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Lowers Price Target to $17

<h3>Gainers</h3>
<ul>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares rose 222.8% to $1.13 during Thursday's pre-market session. The market value of their outstanding shares is at $19.0 million. As per the news, the Q2 earnings report came out 2 days ago. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock moved upwards by 53.51% to $0.2. The company's market cap stands at $2.8 million. </li>
<li>Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) shares increased by 20.84% to $14.32. The market value of their outstanding shares is at $46.5 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) shares increased by 13.78% to $7.8. The company's market cap stands at $23.5 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) shares moved upwards by 12.0% to $0.05. </li>
<li>Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) shares rose 10.05% to $5.3. The company's market cap stands at $112.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock decreased by 50.5% to $6.52 during Thursday's pre-market session. The market value of their outstanding shares is at $37.5 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares fell 21.8% to $1.22. The company's market cap stands at $1.9 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock decreased by 14.56% to $0.07. The market value of their outstanding shares is at $1.0 million. </li>
<li>ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) stock fell 11.68% to $22.01. The company's market cap stands at $741.6 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares fell 10.95% to $0.76. The market value of their outstanding shares is at $2.8 million. </li>
<li>Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) stock fell 10.5% to $5.8. The market value of their outstanding shares is at $19.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ADTX

AVBP

BMRA

ENTA

GCTK

HSDT

SLXN

SRZN

TENX

TRAW

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 150 points on Thursday.
The Dow traded down 0.27% to 43,106.65 while the NASDAQ fell 0.79% to 19,356.43. The S&amp;P 500 also fell, dropping, 0.28% to 5,933.22.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Utilities shares surged by 2.3% on Thursday.
In trading on Thursday, consumer discretionary shares fell by 1.1%.
Top Headline
On Thursday, Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) reported upbeat earnings for its fourth quarter.
The bank posted fourth-quarter adjusted EPS of $2.22, up from $0.85 a year ago and beating the consensus of $1.70. Net earnings more than doubled from $1.52 billion to $3.7 billion.
The U.S. bank reported fourth-quarter revenue of $16.22 billion, up 26% year over year, beating the consensus of $15.03 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares shot up 102% to $0.6820 after the company announced its Fortel Prostate Specific Antigen Screening Test received approval from the United Arab Emirates Ministry of Health and Prevention.</li>
<li>Shares of DouYu International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>)got a boost, surging 26% to $15.53 as the company appointed Simin Ren as Co-CEO and declared a special cash dividend.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares were also up, gaining 19% to $31.88 after the company disclosed a deal to acquire Walmart Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) Advanced Systems and Robotics business.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Leafly Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares dropped 45% to $0.8001 after the company announced it received a Nasdaq desliting notice and will transition to the over-the-counter market.</li>
<li>Shares of Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) were down 34% to $8.70 after the company issued regulatory and business update on EBVALLOTM (tabelecleucel).</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) was down, falling 11% to $1.09 after the company reported preliminary third-quarter revenue of $551 million, down 10% year over year, citing lower volume and competitive market conditions.</li>
</ul>
Commodities In commodity news, oil traded down 1.9% to $78.49 while gold traded up 1.4% at $2,755.10.
Silver traded up 1% to $31.860 on Thursday, while copper rose 1.1% to $4.4350.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 surged 0.98%, Germany's DAX 40 gained 0.39% and France's CAC 40 gained 2.14%. Spain's IBEX 35 Index fell 0.49%, while London's FTSE 100 gained 1.09%.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei 225 gaining 0.33%, China's Shanghai Composite Index gaining 0.28%, Hong Kong's Hang Seng Index climbing 1.23% and India's BSE Sensex rising 0.42%.
Economics
<ul>
<li>U.S. retail sales rose 0.4% month-over-month in December versus a revised 0.8% increase in the previous month and down from market estimates of 0.6%.</li>
<li>U.S. initial jobless claims increased by 14,000 from the previous week to 217,000 in the week ending January 11, compared to market estimates of 210,000.</li>
<li>Import prices increased by 0.1% from the previous month in December, while export prices gained by 0.3% in December.</li>
<li>The Philadelphia Fed Manufacturing Index rose to 44.3 in January compared to a revised reading of -10.9 in the previous month.</li>
<li>The NAHB/Wells Fargo Housing Market Index rose to 47 in January compared to 46 in the prior two months.</li>
<li>U.S. business inventories increased by 0.1% month-over-month in November compared to a revised flat reading in the previous month.</li>
<li>U.S. natural-gas stocks fell 258 billion cubic feet during the week ending Jan. 1, the EIA said.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43025282/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

DOYU

LFLY

PSNY

Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.1% on Thursday.
The Dow traded up 0.08% to 43,256.69 while the NASDAQ fell 0.17% to 19,478.76. The S&amp;P 500 also rose, gaining, 0.15% to 5,958.69.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Real estate shares surged by 0.7% on Thursday.
In trading on Thursday, consumer discretionary shares fell by 0.7%.
Top Headline
Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) reported better-than-expected fourth-quarter results.
The bank posted quarterly net income of $6.7 billion (versus $3.1 billion a year ago) and EPS of 82 cents, beating the analyst consensus estimate of 77 cents.
Revenue, net of interest expense, increased 15.0% year over year to $25.35 billion, beating the analyst consensus estimate of $25.19 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares shot up 159% to $0.8763 after the company announced its Fortel Prostate Specific Antigen Screening Test received approval from the United Arab Emirates Ministry of Health and Prevention.</li>
<li>Shares of DouYu International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>)got a boost, surging 26% to $15.50 as the company appointed Simin Ren as Co-CEO and declared a special cash dividend.</li>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) shares were also up, gaining 14% to $296.00 after the company announced it expects to exceed its previously provided 2024 revenue and income guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Leafly Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares dropped 44% to $0.82 after the company announced it received a Nasdaq desliting notice and will transition to the over-the-counter market.</li>
<li>Shares of Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) were down 45% to $7.16 after the company issued regulatory and business update on EBVALLOTM (tabelecleucel).</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) was down, falling 13% to $1.0592 after the company reported preliminary third-quarter revenue of $551 million, down 10% year over year, citing lower volume and competitive market conditions.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $79.24 while gold traded up 1% at $2,743.60.
Silver traded up 0.5% to $31.690 on Thursday, while copper rose 1% to $4.4330.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 surged 0.63%, Germany's DAX 40 gained 0.13% and France's CAC 40 gained 1.83%. Spain's IBEX 35 Index fell 0.54%, while London's FTSE 100 gained 0.82%.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei 225 gaining 0.33%, China's Shanghai Composite Index gaining 0.28%, Hong Kong's Hang Seng Index climbing 1.23% and India's BSE Sensex rising 0.42%.
Economics
<ul>
<li>U.S. retail sales rose 0.4% month-over-month in December versus a revised 0.8% increase in the previous month and down from market estimates of 0.6%.</li>
<li>U.S. initial jobless claims increased by 14,000 from the previous week to 217,000 in the week ending January 11, compared to market estimates of 210,000.</li>
<li>Import prices increased by 0.1% from the previous month in December, while export prices gained by 0.3% in December.</li>
<li>The Philadelphia Fed Manufacturing Index rose to 44.3 in January compared to a revised reading of -10.9 in the previous month.</li>
<li>The NAHB/Wells Fargo Housing Market Index rose to 47 in January compared to 46 in the prior two months.</li>
<li>U.S. business inventories increased by 0.1% month-over-month in November compared to a revised flat reading in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43025282/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>

SEZL

Crude Oil Down 1%; Bank of America Posts Upbeat Earnings

U.S. stocks traded slightly lower this morning, with the Dow Jones index falling around 0.2% on Thursday.
Following the market opening Thursday, the Dow traded down 0.19% to 43,137.38 while the NASDAQ fell 0.11% to 19,489.02. The S&amp;P 500 also fell, dropping, 0.03% to 5,947.83.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Utilities shares surged by 0.8% on Thursday.
In trading on Thursday, consumer discretionary shares fell by 0.6%.
Top Headline
U.S. retail sales rose 0.4% month-over-month in December versus a revised 0.8% increase in the previous month and down from market estimates of 0.6%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares shot up 246% to $1.1700 after the company announced its Fortel Prostate Specific Antigen Screening Test received approval from the United Arab Emirates Ministry of Health and Prevention.</li>
<li>Shares of Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)got a boost, surging 50% to $3.5204.</li>
<li>DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) shares were also up, gaining 45% to $6.18.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Leafly Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares dropped 48% to $0.7592 after the company announced it received a Nasdaq desliting notice and will transition to the over-the-counter market.</li>
<li>Shares of Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) were down 45% to $7.22 after the company issued regulatory and business update on EBVALLOTM (tabelecleucel).</li>
<li>LuxUrban Hotels Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) was down, falling 44% to $0.3825. LuxUrban Hotels recently issued FY25 revenue guidance.</li>
</ul>
Commodities In commodity news, oil traded down 0.6% to $79.58 while gold traded up 1.1% at $2,748.40.
Silver traded up 0.8% to $31.785 on Thursday, while copper rose 0.6% to $4.4155.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 surged 0.9%, Germany's DAX 40 gained 0.4% and France's CAC 40 gained 2.1%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 gained 1%.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei 225 gaining 0.33%, China's Shanghai Composite Index gaining 0.28%, Hong Kong's Hang Seng Index climbing 1.23% and India's BSE Sensex rising 0.42%.
Economics
<ul>
<li>U.S. retail sales rose 0.4% month-over-month in December versus a revised 0.8% increase in the previous month and down from market estimates of 0.6%.</li>
<li>U.S. initial jobless claims increased by 14,000 from the previous week to 217,000 in the week ending January 11, compared to market estimates of 210,000.</li>
<li>Import prices increased by 0.1% from the previous month in December, while export prices gained by 0.3% in December.</li>
<li>The Philadelphia Fed Manufacturing Index rose to 44.3 in January compared to a revised reading of -10.9 in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43025282/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>

DATS

LUXH

WHLR

US Stocks Edge Lower; Retail Sales Increase Less Than Expected

Atara received FDA Complete Response Letter (CRL) solely related to inspection findings at third-party manufacturer
CRL did not identify deficiencies related to clinical efficacy or safety data in the Biologics License Application (BLA), and the FDA did not request any new clinical studies to support approval
Atara remains committed to working with the FDA, Pierre Fabre Laboratories, and the third-party manufacturer to bring EBVALLO to patients in the U.S.
Atara has engaged a well-known financial advisor to support exploration of all strategic options
Atara remains focused on preserving future EBVALLO financial value for the benefit of all stockholders
Atara has entered into a non-binding term sheet with Redmile Group to provide up to $15 million in funding, which Atara believes is sufficient to fund the ongoing activities required to achieve BLA approval
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;esheet=54181246&amp;newsitemid=20250116967931&amp;lan=en-US&amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;index=1&amp;md5=9226b8c5857f17efdf6e9037fd00fdcd">Atara Biotherapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLOTM (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen.
The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO. The CRL did not identify any deficiencies related to the manufacturing process, the clinical efficacy, or clinical safety data in the BLA, and the FDA did not request any new clinical trials to support the approval of EBVALLO.

Atara Receives FDA CRL Citing Third-Party Manufacturer Inspection For EBVALLO; No Clinical Deficiencies Noted; $15M Funding Secured From Redmile Group To Support BLA Approval Efforts; Engages In Strategic Options Exploration With Financial Advisor; Focus On Preserving Future Value

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) shares increased by 43.8% to $0.31 during Tuesday's pre-market session. The company's market cap stands at $50.3 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock increased by 22.33% to $2.41. The market value of their outstanding shares is at $13.7 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) shares rose 21.12% to $0.92. The market value of their outstanding shares is at $29.4 million. </li>
<li>Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) stock rose 17.26% to $8.15. The company's market cap stands at $403.7 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock rose 15.44% to $18.69. The market value of their outstanding shares is at $107.6 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock increased by 12.3% to $1.46. The market value of their outstanding shares is at $75.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares declined by 42.7% to $3.78 during Tuesday's pre-market session. The company's market cap stands at $6.5 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares fell 21.56% to $0.63. The company's market cap stands at $2.0 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares fell 21.32% to $1.55. The company's market cap stands at $6.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock decreased by 21.26% to $2.89. The market value of their outstanding shares is at $4.1 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) shares decreased by 14.8% to $0.49. The market value of their outstanding shares is at $3.7 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares decreased by 12.98% to $2.08. The market value of their outstanding shares is at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATPC

AVGR

AZTR

CODX

GTBP

IMRN

PHIO

PIII

RGNX

SLRX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Rodman &amp; Renshaw analyst Tony Butler initiates coverage on Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Buy rating and announces Price Target of $25.

Initiation

Rodman & Renshaw Initiates Coverage On Atara Biotherapeutics with Buy Rating, Announces Price Target of $25

WIIM

Atara Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 sales results. Also, Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $13 to $21.

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Buy and raises the price target from $13 to $21.

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $21

Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.50) by 17.2 percent. The company reported quarterly sales of $40.190 million which beat the analyst consensus estimate of $35.168 million by 14.28 percent. This is a 1.78K percent increase over sales of $2.138 million the same period last year.

Atara Biotherapeutics Q3 2024 GAAP EPS $(2.93) Misses $(2.50) Estimate, Sales $40.190M Beat $35.168M Estimate

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Legal

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Comments

Atara Biotherapeutics

空売り

Atara Biotherapeutics (NASDAQ:ATRA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル